Rexahn: Investor Presentation (Rexahn Pharmaceuticals, Inc) - Nov 21, 2015 - “Safe and well tolerated at the doses tested to date”; “2 patients experienced stable disease persisting up to 170 and 334 days (as of Oct 28/2015)”; “1 patient with stable disease experienced a 15% tumor reduction after 4 cycles of therapy”
P2a data • Oncology • Renal Cell Carcinoma
|